PHARMACOLOGY

Sharyn BAKER

SITE

Molecules. 2022;27:6815. Itraconazole-induced increases in Gilteritinib exposure are mediated by CYP3A and OATP1B. Garrison DA, Jin Y, Talebi Z, Hu S, Sparreboom A, Baker SD, Eisenmann ED. PubMed

Pharmaceutics. 2022;14:1933. A metabolomics approach for predicting OATP1B-type transporter-mediated Drug-Drug Interaction liabilities. Li Y, Jin Y, Taheri H, Schmidt KT, Gibson AA, Buck SAJ, Eisenmann ED, Mathijssen RHJ, Figg WD, Baker SD, Sparreboom A, Hu S. PubMed

J Chromatogr B Analyt Technol Biomed Life Sci. 2022;1210:123437.Determination of the endogenous OATP1B biomarkers glycochenodeoxycholate-3-sulfate and chenodeoxycholate-24-glucuronide in human and mouse plasma by a validated UHPLC-MS/MS method. Jin Y, Li Y, Eisenmann ED, Figg WD, Baker SD, Sparreboom A, Hu S. PubMed

Pharmaceutics. 2022;14:694. Interaction of antifungal drugs with CYP3A- and OATP1B-mediated Venetoclax elimination. Eisenmann ED, Garrison DA, Talebi Z, Jin Y, Silvaroli JA, Kim JG, Sparreboom A, Savona MR, Mims AS, Baker SD. PubMed

Basic Clin Pharmacol Toxicol. 2022;130 Suppl 1:23-35. Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions. Eisenmann ED, Talebi Z, Sparreboom A, Baker SD.  PubMed

J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1179:122882. Development, validation, and application of an LC-MS/MS method for the determination of the AXL/FLT3 inhibitor gilteritinib in mouse plasma. Garrison DA, Jin Y, Uddin ME, Sparreboom A, Baker SD. PubMed

Proc Natl Acad Sci U S A. 2021;118:e2020168118. Targeting OCT3 attenuates doxorubicin-induced cardiac injury. Huang KM, Zavorka Thomas M, Magdy T, Eisenmann ED, Uddin ME, DiGiacomo DF, Pan A, Keiser M, Otter M, Xia SH, Li Y, Jin Y, Fu Q, Gibson AA, Bonilla IM, Carnes CA, Corps KN, Coppola V, Smith SA, Addison D, Nies AT, Bundschuh R, Chen T, Lustberg MB, Wang J, Oswald S, Campbell MJ, Yan PS, Baker SD, Hu S, Burridge PW, Sparreboom A. PubMed

Pharmaceutics. 2020;12:E856. Role of OATP1B1 and OATP1B3 in Drug-Drug interactions mediated by Tyrosine Kinase Inhibitors. Garrison DA, Talebi Z, Eisenmann ED, Sparreboom A, Baker SD. PubMed

Clin Transl Sci. 2020;In press. DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia. Buelow DR, Anderson JT, Pounds SB, Shi L, Lamba JK, Hu S, Gibson AA, Goodwin EA, Sparreboom A, Baker SD. PubMed

Pharmaceutics. 2020;12:E788. Influence of Probenecid on the pharmacokinetics and pharmacodynamics of Sorafenib. Hussaarts KGAM, van Doorn L, Eechoute K, Damman J, Fu Q, van Doorn N, Eisenmann ED, Gibson AA, Oomen-de Hoop E, de Bruijn P, Baker SD, Koolen SLW, van Gelder T, van Leeuwen RWF, Mathijssen RHJ, Sparreboom A, Bins S. PubMed

Drug Metab Dispos. 2020;48:419-425. A. Role of OATP2B1 in drug absorption and drug-drug interactions. Chen M, Hu S, Li Y, Gibson AA, Fu Q, Baker SD, Sparreboom. PubMed

Pharmacol Res Perspect. 2019;7:e00534. Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice. Anderson JT, Hu S, Fu Q, Baker SD, Sparreboom A. PubMed

Clin Cancer Res. 2019;25:7320-7330. Sorafenib population pharmacokinetics and skin toxicities in children and adolescents with refractory/relapsed Leukemia or Solid Tumor Malignancies. Inaba H, Panetta JC, Pounds SB, Wang L, Li L, Navid F, Federico SM, Eisenmann ED, Vasilyeva A, Wang YD, Shurtleff S, Pui CH, Gruber TA, Ribeiro RC, Rubnitz JE, Baker SD. PubMed

Clin Pharmacol Ther. 2019;In press. Sorafenib activity and disposition in liver cancer does not depend on Organic Cation Transporter 1. Chen M, Neul C, Schaeffeler E, Frisch F, Winter S, Schwab M, Koepsell H, Hu S, Laufer S, Baker SD, Sparreboom A, Nies AT. PubMed

Clin Transl Sci. 2019;12:400-407. Interaction between sex and Organic Anion-Transporting Polypeptide 1b2 on the pharmacokinetics of Regorafenib and its metabolites Regorafenib-N-Oxide and Regorafenib-Glucuronide in mice. Fu Q, Chen M, Anderson JT, Sun X, Hu S, Sparreboom A, Baker SD. PubMed

J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1090:43-51. Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma. Fu Q, Chen M, Hu S, McElroy CA, Mathijssen RH, Sparreboom A, Baker SD. PubMed

Clin Pharmacol Ther. 2017;102:726-730. Kinase inhibitors: the reality behind the success. Jeon JY, Sparreboom A1, Baker SD. PubMed

Clin Transl Sci. 2017;10:271-279. Influence of OATP1B1 function on the disposition of Sorafenib-β-D-Glucuronide. Bins S, van Doorn L, Phelps MA, Gibson AA, Hu S, Li L, Vasilyeva A, Du G, Hamberg P, Eskens F, de Bruijn P, Sparreboom A, Mathijssen R, Baker SD. PubMed

Clin Transl Sci. 2017 Sep;10:412-420. Identification of OAT1/OAT3 as contributors to Cisplatin toxicity. Hu S, Leblanc AF, Gibson AA, Hong KW, Kim JY, Janke LJ, Li L, Vasilyeva A, Finkelstein DB, Sprowl JA, Sweet DH, Schlatter E, Ciarimboli G, Schellens J, Baker SD, Pabla N, Sparreboom A. PubMed

Cancer Res. 2017;77:2102-2111. OCTN1 Is a high-affinity carrier of nucleoside analogues.Drenberg CD, Gibson AA, Pounds SB, Shi L, Rhinehart DP, Li L3 Hu S, Du G, Nies AT, Schwab M, Pabla N, Blum W, Gruber TA, Baker SD, Sparreboom A. PubMed

Cancer Chemother Pharmacol. 2016;77:1039-52. Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice. Edginton AN, Zimmerman EI, Vasilyeva A, Baker SD, Panetta JC. PubMed

Nat Commun. 2016 Mar 16;7:10880. A phosphotyrosine switch regulates organic cation transporters. Sprowl JA, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L5, Bharill S, Ness RA, Stecula A, Offer SM, Diasio RB, Nies AT, Schwab M, Cavaletti G, Schlatter E, Ciarimboli G, Schellens JH, Isacoff EY, Sali A, Chen T, Baker SD, Sparreboom A, Pabla N. PubMed

Clin Transl Sci. 2016;9:51-9. ABCC4 is a determinant of Cytarabine-induced cytotoxicity and myelosuppression. Drenberg CD, Hu S, Li L, Buelow DR, Orwick SJ, Gibson AA, Schuetz JD, Sparreboom A, Baker SD. PubMed

Cancer Res. 2016;76:117-26. Multikinase inhibitors induce cutaneous toxicity through OAT6-mediated uptake and MAP3K7-driven cell death. Zimmerman EI, Gibson AA, Hu S, Vasilyeva A, Orwick SJ, Du G, Mascara GP, Ong SS, Chen T, Vogel P, Inaba H, Maitland ML, Sparreboom A, Baker SD. PubMed

Clin Pharmacol Ther. 2016;99:651-60. Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Drenberg CD, Paugh SW, Pounds SB, Shi L, Orwick SJ, Li L, Hu S, Gibson AA, Ribeiro RC, Rubnitz JE, Evans WE, Sparreboom A, Baker SD. PubMed

Clin Pharmacol Ther. 2015;98:266-87. Human ontogeny of drug transporters: review and recommendations of the Pediatric Transporter Working Group. Brouwer KL, Aleksunes LM, Brandys B, Giacoia GP, Knipp G, Lukacova V, Meibohm B, Nigam SK, Rieder M, de Wildt SN; Pediatric Transporter Working Group. PubMed

Cancer Res. 2015;75:2729-36. Hepatocellular shuttling and recirculation of Sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a/1b. Vasilyeva A, Durmus S, Li L, Wagenaar E, Hu S, Gibson AA, Panetta JC, Mani S, Sparreboom A, Baker SD, Schinkel AH. PubMed

Br J Cancer. 2014;110:894-8. Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Hu S, Mathijssen RH, de Bruijn P, Baker SD, Sparreboom A. PubMed

Clin Cancer Res. 2014;20:985-94. Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Nies AT1, Schaeffeler E, van der Kuip H, Cascorbi I, Bruhn O, Kneba M, Pott C, Hofmann U, Volk C, Hu S, Baker SD, Sparreboom A, Ruth P, Koepsell H, Schwab M. PubMed

Clin Cancer Res. 2013;19:4359-4370. Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib. Furmanski BD, Hu S, Fujita KI, Li L, Gibson AA, Janke LJ, Williams RT, Schuetz JD, Sparreboom A, Baker SD. PubMed

Clin Cancer Res. 2013;19:1458-66. Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick SJ, Li L, Sparreboom A, Baker SD. PubMed

Clin Pharmacol Ther. 2012;92:642-50. OATP1B1 polymorphism as a determinant of erythromycin disposition. Lancaster CS, Bruun GH, Peer CJ, Mikkelsen TS, Corydon TJ, Gibson AA, Hu S, Orwick SJ, Mathijssen RH, Figg WD, Baker SD, Sparreboom A. PubMed

Clin Cancer Res. 2012;18:4433-40. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, de Bruijn P, Hu S, Gibson AA, Bruun GH, Corydon TJ, Mikkelsen TS, Walker AL, Du G, Loos WJ, van Schaik RH, Baker SD, Mathijssen RH, Sparreboom A. PubMed

Mol Cancer Ther. 2012;11:921-9. Inhibition of OCTN2-mediated transport of carnitine by etoposide. Hu C, Lancaster CS, Zuo Z, Hu S, Chen Z, Rubnitz JE, Baker SD, Sparreboom A. PubMed

Clin Pharmacol Ther. 2011;89:693-701.  Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Franke RM, Lancaster CS, Peer CJ, Gibson AA, Kosloske AM, Orwick SJ, Mathijssen RH, Figg WD, Baker SD, Sparreboom A. PubMed

Clin Cancer Res. 2009;15:6062-9. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD. PubMed

Clin Pharmacol Ther. 2008;84:704-9. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Franke RM, Baker SD, Mathijssen RH, Schuetz EG, Sparreboom A. PubMed

Clin Pharmacol Ther. 2009;85:155-63. Pharmacogenetic pathway analysis of docetaxel elimination. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A. PubMed

Clin Cancer Res. 2008;14:3141-8. Interaction of imatinib with human organic ion carriers. Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, Burger H, Baker SD, Sparreboom A. PubMed

Cancer Biol Ther. 2007;6:432-8. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, Hidalgo M, Baker SD. PubMed

Clin Pharmacol Ther. 2006;80:192-201. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K. PubMed